Tutti gli studi
ReclutamentoFASE1, FASE2INTERVENTISTICO

Study of IDE196 in Patients With Solid Tumors Harboring GNAQ/11 Mutations or PRKC Fusions

This research study is investigating a new medication called IDE196 for people with certain advanced solid cancers, including a type of eye cancer called uveal melanoma, skin cancer, or bowel cancer. These cancers must have particular genetic faults, known as GNAQ/11 mutations or PRKC fusions. The main goals are to find out if IDE196 is safe and how well it works. Researchers are testing IDE196 on its own and in combination with two other approved cancer drugs, binimetinib and crizotinib. The study has different stages: an early stage (Phase 1) to find the right dose, and a later stage (Phase 2) to see how effective that dose is. Some parts of the study looking at IDE196 alone or with binimetinib have already finished taking new patients.

A colpo d'occhio

Stato
Reclutamento
Fase
FASE1, FASE2
Sponsor
IDEAYA Biosciences
Obiettivo di iscrizione
336
Inizio
28 Giugno 2019
Completamento stimato
15 Jun 2027

Di cosa tratta questo studio?

This research study is designed to help us learn more about a new medicine called IDE196. It's for people who have advanced solid cancers, which means the cancer has spread from where it started. Specifically, it's for cancers that have certain genetic changes or 'faults' – imagine a tiny spelling mistake in the cancer's instruction manual – called GNAQ or GNA11 mutations, or PRKC fusions. These faults can be found in different types of cancer, including melanoma (a type of skin cancer, and specifically a rare kind that affects the eye called uveal melanoma) and bowel cancer, as well as other solid tumours.

The main idea behind this study is to see if IDE196 can safely and effectively treat these cancers. Researchers are testing IDE196 in a few ways: they're giving it on its own, and they're also trying it in combination with two other existing cancer drugs, binimetinib and crizotinib. The study is split into stages. Earlier stages focused on finding the safest and most effective dose of IDE196, both by itself and in combination with the other drugs. Later stages focused on seeing how well these doses work against the cancer.

It's important to know that some parts of this study have already finished taking new patients. For example, the parts looking at IDE196 on its own and IDE196 combined with binimetinib are no longer enrolling. This kind of research helps doctors understand new treatments better, so they can find new ways to help people living with cancer.

Punti chiave

  • This study investigates a new drug, IDE196, for advanced cancers with specific genetic changes.
  • It's exploring IDE196 alone and in combination with other existing cancer drugs.
  • The study aims to check the safety and effectiveness of IDE196.
  • It targets cancers like uveal melanoma, cutaneous melanoma, and colorectal cancer.
  • Some parts of the study are no longer accepting new patients.

Chi può essere idoneo?

To join this study, you need to be at least 18 years old. You must have a diagnosis of certain advanced solid cancers, such as metastatic uveal melanoma (a type of eye cancer that has spread), cutaneous melanoma (skin cancer), or bowel cancer, and these cancers need to have specific genetic changes (GNAQ/11 mutations or PRKC fusions). Your cancer might be new or it might have come back after previous treatments.

There are also some general health checks. For example, your organs (like your liver and kidneys) need to be working well, and you should be generally well enough to take part. For women who could become pregnant and men, you would need to use effective birth control during the study.

Some things might mean you can't join. For instance, if you've already had a specific type of treatment called a PKC inhibitor, or if you have certain infections like HIV or active Hepatitis B or C. Also, if your cancer has spread to your brain and is causing symptoms, you usually wouldn't be able to join. Your doctor will carefully review all your medical information to see if this study is right for you.

Questo studio potrebbe fare al caso tuo?

Rispondi a queste domande rapide per vedere se potresti essere idoneo. Questo è solo una guida — il team di ricerca prende la decisione finale.

  1. Hai almeno 18 anni?
  2. Do you have advanced uveal melanoma, cutaneous melanoma, colorectal cancer, or another solid tumour?
  3. Does your cancer have GNAQ/11 mutations or PRKC fusions?
  4. Are you generally well enough to take part and do your organs work properly?
  5. Have you discussed birth control if you are of childbearing potential?
Rispondi a ogni domanda per vedere il tuo risultato.

Cosa comporta la partecipazione?

If you join this study, you would receive the new drug IDE196, either on its own or in combination with binimetinib or crizotinib. The study involves regular visits to the hospital for checks, which would include blood tests, scans (like CT scans) to see how the cancer is responding, and general health assessments. You'd also be asked questions about how you're feeling and any side effects you might be experiencing. Some people might need to have a new biopsy (a small sample of tissue taken) if the doctors need more information about their cancer. The exact number of visits and the total length of time you'd be in the study would depend on which part of the study you join and how your body responds to the treatment. This will all be explained in detail by the study team.

Rischi e benefici potenziali

Taking part in a clinical trial may offer potential benefits, such as access to a new treatment (IDE196) that isn't widely available yet, which might help your cancer. However, there are also potential risks, as IDE196 is an experimental drug, and its full side effects are still being understood. You might experience side effects common to other cancer treatments, or entirely new ones. The study team will closely monitor you for any side effects. It's very important to remember that you are free to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Luoghi (15)

  • UCLA Medical Center
    Codice postale verificato
    Los Angeles, Stati Uniti· Reclutamento
  • San Francisco Oncology Associates
    Codice postale verificato
    San Francisco, Stati Uniti· Attivo ma non reclutante
  • SCRI - Denver
    Codice postale verificato
    Denver, Stati Uniti· Reclutamento
  • Università dell'Iowa
    Codice postale verificato
    Iowa City, Stati Uniti· Attivo ma non reclutante
  • Cancer Hematology Centers Western Michigan
    Codice postale verificato
    Grand Rapids, Stati Uniti· Attivo ma non reclutante
  • Columbia University Medical Center - Herbert Irving Pavilion
    Codice postale verificato
    New York, Stati Uniti· Attivo ma non reclutante
  • Duke University Medical Center
    Codice postale verificato
    Durham, Stati Uniti· Reclutamento
  • University of Cincinnati Cancer Center
    Codice postale verificato
    Cincinnati, Stati Uniti· Reclutamento
  • The Cleveland Clinic Foundation
    Codice postale verificato
    Cleveland, Stati Uniti· Attivo ma non reclutante
  • Sidney Kimmel Cancer Center at Thomas Jefferson University
    Codice postale verificato
    Philadelphia, Stati Uniti· Reclutamento
  • The Sarah Cannon Research Institute/Tennessee Oncology
    Codice postale verificato
    Nashville, Stati Uniti· Reclutamento
  • Centro Oncologico MD Anderson dell'Università del Texas
    Codice postale verificato
    Houston, Stati Uniti· Reclutamento

Domande comuni

What is IDE196?

IDE196 is a new experimental drug being tested to treat certain advanced cancers with specific genetic changes.

What kind of cancers is this study for?

This study is for advanced solid cancers like a type of eye cancer (uveal melanoma), skin cancer (cutaneous melanoma), or bowel cancer, that have specific genetic changes called GNAQ/11 mutations or PRKC fusions.

Is IDE196 given alone or with other drugs?

IDE196 is being tested both on its own and in combination with two approved cancer drugs, binimetinib and crizotinib.

Are new patients still being accepted into this study?

Some parts of the study, specifically looking at IDE196 alone and IDE196 with binimetinib, have finished taking new patients. Your doctor can tell you if any other parts are still open.

What are GNAQ/11 mutations or PRKC fusions?

These are specific genetic changes or 'faults' found in the cancer cells that the new drug, IDE196, is designed to target.

Come saperne di più

IDEAYA Clinical Trials

Parla sempre con il tuo medico di base o specialista prima di decidere di partecipare a uno studio.

Interessato a partecipare?

Registrati per ricevere aggiornamenti

Condividi i tuoi dettagli e il team di ricerca per "Study of IDE196 in Patients With Solid Tumors Harboring GNAQ…" ti contatterà se potresti essere idoneo. Parla sempre con il tuo medico prima di accettare di partecipare.

Discussione

Discussione della comunità

Supportato dal nostro forum su community.patient.info. Si prega di essere rispettosi — questo non è un consiglio medico.